InvestLog
ATAI Atai Beckley N.V logo

ATAI Atai Beckley N.V

Healthcare
$4.32-0.23%ClosedMarket Cap: $1.59B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

4.93

P/S

455.99

EV/EBITDA

-12.20

DCF Value

$0.19

FCF Yield

-7.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

82.0%

Operating Margin

-3658.0%

Net Margin

-19019.4%

ROE

-366.5%

ROA

-250.5%

ROIC

-53.1%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$954.0K$-29.8M$—
Q4 null$1.1M$-544.8M$—
FY null$4.1M$-660.0M$—
Q3 null$749.0K$-61.1M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$12.00

Target (Median)

$11.50

Target Range

$10.00 - $15.00

2 Strong Buy12 Buy0 Hold0 Sell0 Strong Sell
Canaccord GenuityBuy
2026-04-20
GuggenheimBuy
2026-04-17
HC Wainwright & Co.Buy
2026-03-17
NeedhamBuy
2026-03-09
Canaccord GenuityBuy
2025-10-22

Trading Activity

Insider Trades

View All
Feilding-Mellen Cosmodirector
SellWed Nov 26
Feilding-Mellen Cosmodirector
SellWed Nov 26
HERSHBERG ROBERTdirector
SellThu Nov 06
HERSHBERG ROBERTdirector
SellThu Nov 06
HERSHBERG ROBERTdirector
SellThu Nov 06

Company Info

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Country

NL

Exchange

—

Beta

1.60

Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.

Peers

AMLX logoAMLXDNTH logoDNTHELVN logoELVNIMTX logoIMTXINBX logoINBXNKTR logoNKTRORIC logoORICRLAY logoRLAYSANA logoSANASNDX logoSNDX